Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange

Lancet Haematol. 2021 Nov;8(11):e862. doi: 10.1016/S2352-3026(21)00202-7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Graft vs Host Disease / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / therapy*
  • Humans
  • Male
  • Neoplasm Recurrence, Local / therapy
  • Nivolumab / therapeutic use*
  • Plasma Exchange*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab